These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 15493218)
41. Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR. Zhang P; Bao L; Fan J; Jia ZJ; Sinha U; Wong PW; Park G; Hutchaleelaha A; Scarborough RM; Zhu BY Bioorg Med Chem Lett; 2009 Apr; 19(8):2186-9. PubMed ID: 19297158 [TBL] [Abstract][Full Text] [Related]
42. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate. Wang ZM; Li L; Li B; Guo SY Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476 [TBL] [Abstract][Full Text] [Related]
43. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin. Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514 [TBL] [Abstract][Full Text] [Related]
44. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847 [TBL] [Abstract][Full Text] [Related]
45. Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke. Martí-Fàbregas J; Mateo J Cerebrovasc Dis; 2009; 27 Suppl 1():111-9. PubMed ID: 19342840 [TBL] [Abstract][Full Text] [Related]
46. Perioperative bridging with fondaparinux in a woman with antithrombin deficiency. Bauersachs R; Alban S Thromb Haemost; 2007 Mar; 97(3):498-9. PubMed ID: 17334522 [No Abstract] [Full Text] [Related]
47. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa. Li YL; Fevig JM; Cacciola J; Buriak J; Rossi KA; Jona J; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY Bioorg Med Chem Lett; 2006 Oct; 16(19):5176-82. PubMed ID: 16870435 [TBL] [Abstract][Full Text] [Related]
48. Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor. Andreotti F; Santucci E Thromb Haemost; 2008 Apr; 99(4):651-2. PubMed ID: 18392319 [No Abstract] [Full Text] [Related]
49. Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation. Hammwöhner M; Goette A J Cardiovasc Pharmacol; 2008 Jul; 52(1):18-27. PubMed ID: 18594479 [TBL] [Abstract][Full Text] [Related]
50. Emerging anticoagulants for the treatment of venous thromboembolism. Weitz JI Thromb Haemost; 2006 Sep; 96(3):274-84. PubMed ID: 16953267 [TBL] [Abstract][Full Text] [Related]
51. Novel anticoagulants and the future of anticoagulation. Garcia D Thromb Res; 2009; 123 Suppl 4():S50-5. PubMed ID: 19303505 [TBL] [Abstract][Full Text] [Related]
52. Drug evaluation: the directly activated Factor Xa inhibitor otamixaban. Nutescu EA; Pater K IDrugs; 2006 Dec; 9(12):854-65. PubMed ID: 17139573 [TBL] [Abstract][Full Text] [Related]
53. New anticoagulants & clinical trials. Haideri N; Patel H Mo Med; 2009; 106(1):60-4. PubMed ID: 19245126 [TBL] [Abstract][Full Text] [Related]
55. Rivaroxaban for thromboprophylaxis. Lippi G; Franchini M; Targher G N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009674 [No Abstract] [Full Text] [Related]
56. From heparins to factor Xa inhibitors and beyond. Alban S Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143 [TBL] [Abstract][Full Text] [Related]
57. Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners. Wittkowsky AK; Sekreta CM; Nutescu EA; Ansell J Pharmacotherapy; 2005 Feb; 25(2):265-9. PubMed ID: 15767240 [TBL] [Abstract][Full Text] [Related]